Development and optimization of a nanoparticle-based targeted drug delivery system for enhanced anticancer efficacy and reduced systemic toxicity.

Project Abstract

The present study reports the development and optimization of a nanoparticle-based targeted drug delivery system aimed at enhancing anticancer efficacy while minimizing systemic toxicity. A multifaceted design was employed, integrating biocompatible polymeric nanoparticles conjugated with a tumor-specific ligand to achieve active targeting, combined with optimized physicochemical properties (size, charge, surface PEGylation) to maximize tumor accumulation via the enhanced permeation and retention (EPR) effect and receptor-mediated uptake. The synthesis employed a nanoprecipitation technique to produce nanoparticles in the 60–120 nm range with near-neutral zeta potential to reduce nonspecific protein adsorption and accelerate circulation time. The chemotherapeutic payload, a poorly water-soluble anticancer drug, was encapsulated with high loading efficiency and stable retention under physiological conditions, while enabling triggered release in the acidic tumor microenvironment to increase intratumoral drug concentration. A systematic optimization strategy was implemented using design of experiments (DoE) to correlate formulation variables (polymer ratio, crosslinking density, ligand density, and drug loading) with key performance metrics, including particle size distribution, polydispersity index, drug encapsulation efficiency, drug release profile, and in vitro cytotoxicity against a panel of cancer cell lines representing heterogeneous receptor expression. In vitro assessments demonstrated enhanced cellular uptake and cytotoxicity in receptor-positive tumor cells compared with non-targeted controls, with reduced off-target effects in normal cell lines. The targeted nanoparticles exhibited controlled, sustained drug release with a sharp increase in release rate under acidic pH and enzymatic conditions simulating the tumor milieu. In vivo pharmacokinetic and biodistribution studies in a rodent tumor model indicated prolonged circulation half-life and preferential tumor accumulation of the targeted nanosystem, achieving a higher tumor-to-organ uptake ratio than non-targeted formulations. Therapeutic efficacy studies revealed superior tumor growth inhibition and prolonged survival without a corresponding rise in systemic toxicity markers, as evidenced by stable body weight and attenuation of hematological and biochemical perturbations commonly associated with conventional chemotherapy. Mechanistic analyses suggested that receptor-mediated endocytosis facilitated enhanced intracellular drug delivery to lysosomal compartments, where pH-triggered release enabled efficient cytosolic access and apoptotic signaling. Safety evaluations included comprehensive histopathology, organ function tests, and immunogenicity assessments, all showing favorable safety margins for the optimized formulation. The study also encompasses stability assessments under accelerated and real-time conditions, scalability considerations for GMP-compliant manufacturing, and an overall risk–benefit analysis for potential translation. Collectively, the findings demonstrate that the rationally engineered, ligand-targeted, stimulus-responsive nanoparticle platform can achieve a synergistic improvement in anticancer efficacy while reducing systemic toxicity, supporting further translational development toward personalized cancer therapy.

Project Overview

What This Project Is About

---

A plain-language overview of the topic and what the project investigates.

---

---

The Problem It Addresses

---

Current cancer treatments can harm healthy tissues and cause serious side effects. Many drugs spread through the body rather than targeting tumors specifically. This project explores a nanoparticle-based system to deliver drugs directly to cancer cells, aiming to improve effectiveness while reducing harm to healthy cells.

---

---

Objectives of the Project

---

1. Explain how nanoparticles can carry cancer drugs to tumors.
2. Compare targeted delivery with standard administration in terms of potential toxicity.
3. Identify a suitable nanoparticle type and surface features to improve targeting.
4. Assess the stability and safety of the nanoparticle formulation in simple tests.
5. Outline how the system could be produced at a small scale for further study.

---

---

What You Will Do Step by Step

---

1) Review basic concepts of nanoparticles and drug delivery in plain terms.

2) Choose a model drug and tumor target and justify the choice.

3) Design a simple nanoparticle formulation and outline how it would be tested in a lab model.

4) Describe basic data collection methods (effectiveness and safety indicators).

5) Explain how data would be analyzed to compare targeted vs non-targeted delivery.

6) Discuss potential limitations and ethical considerations for future work.

---

---

Expected Outcome

Students should anticipate a clear, beginner-friendly explanation of how targeted nanoparticles could improve cancer treatment, including a basic plan for evaluating effectiveness and safety, and a discussion of real-world implications and next steps.